CG Oncology (NASDAQ:CGON) Price Target Raised to $85.00 at Truist Financial

CG Oncology (NASDAQ:CGON) had its price objective lifted by Truist Financial from $82.00 to $85.00 in a research report released on Friday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on CGON. JPMorgan Chase & Co. lifted their price objective on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research note on Wednesday, July 29th. Royal Bank Of Canada lifted their price target on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Finally, Wolfe Research began coverage on shares of CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating for the company. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $83.18.

CG Oncology Price Performance

CG Oncology stock opened at $75.10 on Friday. The stock has a market capitalization of $6.62 billion, a P/E ratio of -27.92 and a beta of 0.23. The firm’s 50-day moving average is $67.12 and its two-hundred day moving average is $63.95. CG Oncology has a 12-month low of $23.65 and a 12-month high of $77.00.

CG Oncology (NASDAQ:CGON) last released its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The firm had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative return on equity of 26.58% and a negative net margin of 3,602.68%. As a group, analysts forecast that CG Oncology will post -2.89 EPS for the current year.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at $350,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James Mulay sold 24,165 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the sale, the director owned 24,165 shares of the company’s stock, valued at $1,816,241.40. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 37,129 shares of company stock worth $2,663,817 in the last three months. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently bought and sold shares of the business. Jennison Associates LLC acquired a new position in shares of CG Oncology during the 4th quarter valued at $11,730,000. Pictet Asset Management Holding SA increased its holdings in CG Oncology by 2.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,349,527 shares of the company’s stock valued at $56,032,000 after purchasing an additional 30,960 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in CG Oncology by 623.8% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,834 shares of the company’s stock valued at $1,571,000 after purchasing an additional 32,607 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new position in CG Oncology in the fourth quarter valued at about $606,000. Finally, SG Americas Securities LLC raised its position in CG Oncology by 92.7% in the fourth quarter. SG Americas Securities LLC now owns 20,949 shares of the company’s stock valued at $870,000 after purchasing an additional 10,077 shares during the period. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

More CG Oncology News

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.